Permission from DCGI [Drug controller general, India] is needed before which phase of drug trial?
Which of the following drug combinations demonstrates receptor level antagonism?
Which of the following is not a common side effect of clonidine?
Which of the following is a lipid insoluble beta-blocker?
Which non-selective beta-blocker has sympathomimetic activity?
Which of the following pairs are considered physiological antagonists in pharmacology?
Which of the following is an example of topical administration producing only local effects (not systemic)?
Regarding the concepts of efficacy and potency of a drug, which of the following statements is FALSE?
Which antimuscarinic drug is used in overactive bladder?
Which anti-cholinesterase drug is known for its central nervous system activity?
NEET-PG 2015 - Pharmacology NEET-PG Practice Questions and MCQs
Question 11: Permission from DCGI [Drug controller general, India] is needed before which phase of drug trial?
- A. Phase 1
- B. Phase 2
- C. Phase 3 (Correct Answer)
- D. Phase 4
Explanation: ***Phase 3*** - Permission from the **DCGI (Drug Controller General of India)** is mandatory before initiating **Phase 3** clinical trials as per **Schedule Y** of the Drugs and Cosmetics Rules. - Phase 3 trials involve **large-scale studies in Indian patients** to establish efficacy and safety in the target population, requiring explicit regulatory approval. - This is the critical regulatory checkpoint where DCGI evaluates the Phase 1 and 2 data before allowing widespread testing in Indian subjects. *Phase 1* - Phase 1 trials can be conducted after approval from the **Institutional Ethics Committee (IEC)** without requiring prior DCGI permission. - These trials in healthy volunteers focus on safety, pharmacokinetics, and dose-ranging studies. - DCGI is informed but explicit permission is not mandatory at this stage. *Phase 2* - Phase 2 trials also proceed with **IEC approval** and do not require prior DCGI permission. - These trials evaluate therapeutic efficacy and dose determination in a limited number of patients. - Results from Phase 2 are submitted to DCGI when seeking Phase 3 approval. *Phase 4* - Phase 4 trials are **post-marketing surveillance** studies conducted after drug approval. - These are conducted under the Post-Marketing Surveillance (PMS) framework. - While regulatory oversight exists, these are not pre-market trials requiring permission to initiate.
Question 12: Which of the following drug combinations demonstrates receptor level antagonism?
- A. Histamine and Adrenaline
- B. Isoprenaline (agonist) and Propranolol (antagonist) (Correct Answer)
- C. Adrenaline and Isoprenaline
- D. None of the options
Explanation: ***Isoprenaline (agonist) and Propranolol (antagonist)*** - **Propranolol** is a **beta-adrenergic receptor antagonist**, meaning it binds to and blocks beta-adrenergic receptors. - **Isoprenaline** is a **beta-adrenergic receptor agonist**, meaning it activates these same receptors. Their combined action demonstrates **receptor-level antagonism** as propranolol prevents isoprenaline from binding and eliciting its effect. *Histamine and Adrenaline* - This combination illustrates **physiological antagonism**, where two drugs produce opposite effects through different mechanisms and different receptors. - **Adrenaline** causes bronchodilation and vasoconstriction via adrenergic receptors, counteracting the effects of **histamine** (e.g., bronchoconstriction, vasodilation) which acts on histamine receptors. *Adrenaline and Isoprenaline* - Both **adrenaline** and **isoprenaline** are **agonists** of adrenergic receptors, specifically beta-adrenergic receptors. - They would produce similar effects (e.g., increased heart rate, bronchodilation) rather than opposing each other at the receptor level. *None of the options* - This is incorrect because **Isoprenaline and Propranolol** is a valid example of receptor-level antagonism, making this option unnecessary.
Question 13: Which of the following is not a common side effect of clonidine?
- A. Xerostomia
- B. Sedation
- C. Diarrhea (Correct Answer)
- D. Impotency
Explanation: ***Diarrhea*** - **Clonidine** commonly causes **constipation**, not diarrhea, due to its **alpha-2 adrenergic agonist** effects, which decrease gastrointestinal motility. - Diarrhea is not typically associated with clonidine's mechanism of action or adverse effect profile. *Xerostomia* - **Xerostomia** (dry mouth) is a very common side effect of **clonidine** occurring in up to 40% of patients. - This results from **alpha-2 agonist** activity that reduces sympathetic stimulation of salivary gland secretions. - This symptom can significantly impact patient compliance and quality of life. *Sedation* - **Sedation** is a frequent side effect of **clonidine**, particularly when initiating treatment or increasing dosage, because it acts as an **alpha-2 agonist** in the central nervous system, reducing sympathetic outflow and promoting drowsiness. - Patients are often advised to avoid driving or operating heavy machinery until they know how the medication affects them. *Impotency* - **Impotency** or **erectile dysfunction** is a recognized and common sexual side effect of **clonidine**, which can interfere with quality of life and adherence to treatment for hypertension. - This effect is related to the drug's impact on the autonomic nervous system and vascular tone through central alpha-2 agonism.
Question 14: Which of the following is a lipid insoluble beta-blocker?
- A. Timolol
- B. Carvedilol
- C. Pindolol
- D. Celiprolol (Correct Answer)
Explanation: ***Celiprolol*** - **Celiprolol** is a **hydrophilic** (lipid-insoluble) beta-blocker, meaning it has low lipid solubility and does not readily cross the blood-brain barrier. - This property reduces the likelihood of **CNS side effects** such as nightmares and insomnia. *Timolol* - **Timolol** is a **lipophilic** (lipid-soluble) beta-blocker, allowing it to penetrate the central nervous system. - Its high lipid solubility contributes to a higher incidence of **CNS side effects**. *Carvedilol* - **Carvedilol** is a **lipophilic** mixed alpha and beta-blocker, which means it can cross the blood-brain barrier. - This can lead to central nervous system effects, although its primary clinical use is in heart failure and hypertension. *Pindolol* - **Pindolol** is a **lipophilic** beta-blocker with intrinsic sympathomimetic activity (ISA). - Its lipid solubility allows it to enter the brain, potentially causing **CNS-related side effects**.
Question 15: Which non-selective beta-blocker has sympathomimetic activity?
- A. Nadolol
- B. Pindolol (Correct Answer)
- C. Acebutalol
- D. Metoprolol
Explanation: ***Pindolol*** - **Pindolol** is a **non-selective beta-blocker** that exhibits **intrinsic sympathomimetic activity (ISA)**, meaning it acts as a partial agonist at beta-adrenergic receptors. - Due to ISA, it causes less reduction in resting heart rate and cardiac output compared to beta-blockers without ISA. *Acebutalol* - **Acebutalol** is a **beta-1 selective blocker** (cardioselective) that possesses **intrinsic sympathomimetic activity (ISA)**. - While it has ISA, it is not a non-selective beta-blocker, making it an incorrect answer for this question. *Nadolol* - **Nadolol** is a **non-selective beta-blocker** that does **not** have intrinsic sympathomimetic activity (ISA). - It primarily acts as a pure antagonist at both beta-1 and beta-2 adrenergic receptors. *Metoprolol* - **Metoprolol** is a **beta-1 selective blocker** (cardioselective) and does **not** possess intrinsic sympathomimetic activity (ISA). - Its primary action is blockade of cardiac beta-1 receptors.
Question 16: Which of the following pairs are considered physiological antagonists in pharmacology?
- A. Adrenaline and Isoprenaline
- B. Isoprenaline and Propranolol
- C. Histamine and Adrenaline (Correct Answer)
- D. All of the options
Explanation: ***Histamine and Adrenaline*** - **Physiological antagonism** occurs when two drugs produce opposite effects by acting on different receptors or pathways. - **Histamine** causes bronchoconstriction and vasodilation, while **adrenaline** causes bronchodilation and vasoconstriction, counteracting each other's effects through different mechanisms. *Adrenaline and Isoprenaline* - Both **adrenaline** and **isoprenaline** are **adrenergic agonists** that produce similar physiological effects, primarily through beta-adrenergic receptor activation. - They are not physiological antagonists but rather have **synergistic** or similar pharmacological actions. *Isoprenaline and Propranolol* - **Isoprenaline** is a **beta-adrenergic agonist**, while **propranolol** is a **beta-adrenergic antagonist**. - This is an example of **pharmacological antagonism (receptor antagonism)**, where one drug blocks the effect of another at the same receptor site, rather than physiological antagonism.
Question 17: Which of the following is an example of topical administration producing only local effects (not systemic)?
- A. Topical corticosteroid cream (Correct Answer)
- B. Sublingual nitroglycerin
- C. Transdermal patch
- D. Rectal diazepam
Explanation: ***Topical corticosteroid cream*** - When applied to the skin for conditions like dermatitis, topical corticosteroids primarily exert their effects at the site of application, reducing **local inflammation** and itching. - While systemic absorption can occur with potent steroids over large areas, typical use aims for **localized action** without significant systemic effects. *Sublingual nitroglycerin* - This route is designed for **rapid systemic absorption** through the oral mucosa, bypassing first-pass metabolism to quickly treat angina. - The goal is a **widespread vasodilatory effect** throughout the body, not a local one within the mouth. *Transdermal patch* - Transdermal patches, such as those for nicotine or fentanyl, are specifically designed to deliver medication **systemically** through the skin into the bloodstream over a prolonged period. - They provide a **sustained release** and systemic therapeutic effect throughout the body. *Rectal diazepam* - Administered rectally, diazepam is absorbed into the systemic circulation to produce **CNS effects** such as sedation, anxiolysis, or anticonvulsant activity. - Although the administration is local, the intended clinical effect is **systemic** and widespread throughout the body.
Question 18: Regarding the concepts of efficacy and potency of a drug, which of the following statements is FALSE?
- A. ED50 of the drug corresponds to efficacy (Correct Answer)
- B. Drugs that produce a similar pharmacological effect can have different levels of efficacy
- C. In a clinical setup, efficacy is more important than potency
- D. In the log dose response curve, the height of the curve corresponds with efficacy
Explanation: ***ED50 of the drug corresponds to efficacy*** - **ED50** (median effective dose) is the dose at which 50% of individuals exhibit the specified effect; it quantifies **potency**, not efficacy. - **Efficacy** refers to the maximum effect a drug can produce, while potency refers to the amount of drug needed to produce an effect. *In a clinical setup, efficacy is more important than potency* - **Efficacy** determines the maximal therapeutic benefit a drug can achieve for a patient, making it crucial for clinical outcomes. - While **potency** influences the dose required, a highly potent drug that is not very efficacious may not be clinically useful. *Drugs that produce a similar pharmacological effect can have different levels of efficacy* - Two drugs might act on the same receptor but elicit different maximal responses, indicating varying **efficacy**. - For example, a **partial agonist** and **full agonist** interacting with the same receptor will have different efficacies. *In the log dose response curve, the height of the curve corresponds with efficacy* - The **maximal response** or plateau of the dose-response curve represents the **efficacy** of a drug. - A higher plateau on the curve indicates a drug with greater intrinsic activity achieving a larger effect.
Question 19: Which antimuscarinic drug is used in overactive bladder?
- A. Trospium (Correct Answer)
- B. Atropine
- C. Tropicamide
- D. Pirenzepine
Explanation: ***Trospium*** - **Trospium** is a quaternary ammonium compound that acts as an **antimuscarinic agent** primarily used to treat **overactive bladder (OAB)**. - Its **polar nature** limits its ability to cross the blood-brain barrier, reducing central nervous system side effects common with other antimuscarinics. *Tropicamide* - **Tropicamide** is an **antimuscarinic** agent primarily used as a **mydriatic** (to dilate pupils) and **cycloplegic** (to paralyze the ciliary muscle) for ophthalmic examinations. - It has a short duration of action, making it unsuitable for chronic conditions like overactive bladder. *Atropine* - **Atropine** is a non-selective **muscarinic antagonist** with a wide range of uses, including bradycardia, organophosphate poisoning, and ophthalmic procedures. - While it has antimuscarinic effects on the bladder, its systemic side effects (e.g., dry mouth, blurred vision, tachycardia) limit its use for overactive bladder. *Pirenzepine* - **Pirenzepine** is a selective **M1 muscarinic antagonist** primarily used to treat **peptic ulcers** by reducing gastric acid secretion. - Its selectivity for M1 receptors means it has limited efficacy for relieving bladder symptoms, which are primarily mediated by M2 and M3 receptors.
Question 20: Which anti-cholinesterase drug is known for its central nervous system activity?
- A. Physostigmine (Correct Answer)
- B. Edrophonium
- C. Pyridostigmine
- D. Neostigmine
Explanation: ***Physostigmine*** - Unlike most other anti-cholinesterases, **physostigmine** is a **tertiary amine** and is relatively lipid-soluble, allowing it to cross the **blood-brain barrier**. [2] - Its ability to increase acetylcholine in the CNS makes it useful in treating anticholinergic toxicity (e.g., atropine overdose). [2] *Pyridostigmine* - **Pyridostigmine** is a **quaternary amine** and does not readily cross the blood-brain barrier, primarily acting peripherally. - It is mainly used in the long-term management of **myasthenia gravis**. *Edrophonium* - **Edrophonium** is a very short-acting **quaternary amine** that does not cross the blood-brain barrier. [1] - It is primarily used for the **diagnosis of myasthenia gravis** (Tensilon test) due to its rapid onset and short duration of action. [1] *Neostigmine* - **Neostigmine** is also a **quaternary amine** with poor lipid solubility, meaning it has minimal central nervous system activity. [2] - It is commonly used to reverse the effects of **non-depolarizing neuromuscular blockers** and in the treatment of **myasthenia gravis**.